中华皮肤科杂志 ›› 2025, Vol. 58 ›› Issue (8): 715-728.doi: 10.35541/cjd.20250136

• 述评·结缔组织病 • 上一篇    下一篇

红斑狼疮研究的现状与挑战

陆前进    曹淑梅    蒋娇   

  1. 中国医学科学院、北京协和医学院皮肤病医院,南京  210042
  • 收稿日期:2025-03-17 修回日期:2025-06-16 发布日期:2025-08-05
  • 通讯作者: 陆前进 E-mail:qianlu5860@pumcderm.cams.cn
  • 基金资助:
    国家重点研发计划(2022YFC3601800);国家自然科学基金(82430102、32141004);中央级公益性科研院所基本科研业务费专项资金项目(2020-RC320-003);中国医学科学院医学与健康科技创新工程项目(2021-I2M-1-059);湖南省科技创新计划资助 湖湘高层次人才聚集项目(2022RC4026)

Lupus erythematosus research: current status and challenges

Lu Qianjin, Cao Shumei, Jiang Jiao   

  1. Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China 
  • Received:2025-03-17 Revised:2025-06-16 Published:2025-08-05
  • Contact: Lu Qianjin E-mail:qianlu5860@pumcderm.cams.cn
  • Supported by:
    National Key R&D Program of China (2022YFC3601800); National Natural Science Foundation of China (82430102, 32141004); Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2020-RC320-003); CAMS Innovation Fund for Medical Sciences (2021-I2M-1-059); The Science and Technology Innovation Program of Hunan Province (2022RC4026)

摘要: 【摘要】 红斑狼疮是一类临床表现复杂且具有高度异质性的自身免疫性谱系性疾病。一端为仅局限于皮肤损害的皮肤型红斑狼疮,另一端为多器官和多系统损害的系统性红斑狼疮(SLE)。红斑狼疮的发病机制复杂,涉及遗传、环境、激素和免疫等多因素共同作用。近年来,代谢重编程、线粒体功能障碍及肠道菌群失调等新兴机制的发现,为揭示红斑狼疮的发病机制提供新视角。而新型生物标志物的不断涌现及人工智能技术的快速发展为红斑狼疮的早期诊断和精准分型提供了新思路。在治疗方面,生物制剂的应用在传统治疗效果欠佳的SLE患者中取得了突破性进展。然而,红斑狼疮研究仍面临着发病机制尚未完全阐明、早期诊断困难及个体化治疗不足的多重挑战。本文旨在综述红斑狼疮研究的现状与面临的主要挑战,重点讨论发病机制解析、精准诊断技术开发、生物标志物挖掘及新型治疗策略探索等领域的最新进展与未来方向。

关键词: 红斑狼疮, 皮肤, 红斑狼疮, 系统性, 自身免疫, 生物标志物, 靶向治疗策略

Abstract: 【Abstract】 Lupus erythematosus (LE) is a spectrum of autoimmune diseases with complex and highly heterogeneous clinical manifestations. At one end of the spectrum lies cutaneous LE, which is limited to the skin, while at the other end is systemic LE (SLE), which affects multiple organs and systems. The pathogenesis of LE involves the interplay of multiple factors, including genetic predisposition, environmental triggers, hormonal influences, and immune dysregulation. In recent years, emerging mechanisms such as metabolic reprogramming, mitochondrial dysfunction, and gut microbiota dysbiosis have provided new perspectives for understanding the pathogenesis of LE. Additionally, the discovery of novel biomarkers and the rapid development of artificial intelligence technologies have opened new avenues for early diagnosis and precise classification of LE. In terms of treatment, the introduction of biologic agents has marked a significant breakthrough in managing SLE patients who respond poorly to conventional therapies. However, LE research still faces multiple challenges, including incomplete understanding of its pathogenesis, difficulties in early diagnosis, and insufficient personalized treatment approaches. This article aims to provide a comprehensive review of the current status and major challenges in LE research, focusing on advances in elucidation of pathogenesis, discovery of biomarkers, as well as development of precision diagnostic tools and novel therapeutic strategies.

Key words: Lupus erythematosus, cutaneous, Lupus erythematosus, systemic, Autoimmunity, Biomarkers, Targeted therapeutic strategies

引用本文

陆前进 曹淑梅 蒋娇. 红斑狼疮研究的现状与挑战[J]. 中华皮肤科杂志, 2025,58(8):715-728. doi:10.35541/cjd.20250136

Lu Qianjin, Cao Shumei, Jiang Jiao. Lupus erythematosus research: current status and challenges[J]. Chinese Journal of Dermatology, 2025, 58(8): 715-728.doi:10.35541/cjd.20250136